SNGX (Soligenix, Inc.) Forward P/E Multiple

Public company logo of Soligenix (SNGX)

Soligenix, Inc. (SNGX) strictly adheres to environmental regulations by implementing energy conservation and emission filtration. After evaluating the company's future P/E ratio on GURU.Markets, we find that 0.00 determines the latest valuation metric. This price action is based on lymphoma therapy test results and government grants for vaccines, as well as the stability of a compact team of experts incentivized by stock options.

Price to Future Earnings Ratio: Soligenix, Inc. (SNGX) for 07/04/2022 - 11/12/2026

Summary analytical data breakdowns for BioPharma Bio (SNGX)

- current price and projected stock value:
Stock Quotes Soligenix, Inc.|SNGX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Soligenix Inc|SNGX - Company Buyout Price
- book capitalization information:
Net Assets per Single Share Soligenix|SNGX - Accounting Capitalization|Market Capitalization to Book Value Ratio soligenix.com|SNGX - Total Asset Value of Company
- debt and liquidity details:
Total Debt to Capital Soligenix, Inc.|SNGX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Soligenix, Inc.|SNGX - Company Total Debt|Debt to Book Value Soligenix Inc|SNGX - Amount of Long-Term Liabilities|Company Short-Term Debts Soligenix|Quick Liquidity soligenix.com
- company profitability and valuation multiples indicators:
SNGX - Company Net Income|Expected Profit Soligenix, Inc.|SNGX - Price to Earnings Multiple|Future Price to Earnings Soligenix, Inc.|SNGX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Soligenix Inc|SNGX - Operating income before deduction of amortization|Earnings per share for the last twelve months Soligenix|SNGX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months soligenix.com|SNGX - Earnings per share growth in current year|Earnings growth forecast for next year Soligenix, Inc.
Fundamental company analysis:Soligenix SNGX
Brand item of BioPharma Bio

The forward P/E determines the ratio of the current market value of Soligenix, Inc. (SNGX) to the projected net income for the following year, measuring market expectations regarding the asset's future returns. By analyzing the forward P/E chart for Soligenix, Inc. (SNGX), an investor can see the valuation's sensitivity to R&D cycles, which is critical for a startup developing a pipeline of orphan drugs aimed at accelerated market entry.

Key competitors

Projected Price to Earnings SMMT (Summit Therapeutics Inc.)|MRNA (Moderna Inc) - Future Price to Earnings Multiple|Forward P/E Multiple PCVX (Vaxcyte Corp)|Market Cap to Projected Earnings Tarsus Corp (TARS)|CRMD - Future Price to Earnings|MCRB (serestherapeutics.com) - Price to Future Earnings Ratio|SPRO: Forward P/E Multiple|Price to Expected Earnings Ratio SCYX (SCYNEXIS)|ANTX (AN2 Therapeutics Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio PolyPid Limited PYPD|Forward P/E Multiple LSB|Projected Price to Earnings iterumtx.com ITRM|BiomX - Projected Price to Earnings|Market Cap to Future Earnings Ratio SXTP (60 Degrees Pharmaceuticals Inc.)|Oragenics - Forward P/E Multiple|Market Cap to Projected Earnings OpGen Corporation OPGN